|
|
Article: CureVac Completes [euro]35M Round For mRNA Product Development.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
CureVac GmbH raised an additional C13 million in its Series B financing, taking the round's total to C35 million (US$48 million).
The Tubingen, Germany-based company will use funds for development of messenger RNA-based cancer immunotherapeutics for various indications. CureVac said its RNActive technology platform for developing cancer vaccines allows for the construction of long-chain mRNA molecules suitable for human therapeutic applications.
"The additional funds will allow us to make optimal use of RNActive for tumor therapy," Thomas Lander, managing director and chief medical officer of CureVac, said in a news release. "We ...
Related newspaper, magazine, and journal articles:
|
|
Article: Clinical Data and Duke University in ...
Business Wire;
May 12, 2006 ;
700+ words
... ... cholesterol). In return, Clinical Data receives the right to ... IGSP studies. Should Clinical Data be interested in any ... IGSP are planning a series of studies to find and ... Chief Medical Officer of Clinical Data, said, "We are very ...
|
|